Viracta Therapeutics (VIRX) Short Interest Ratio & Short Volume $0.02 +0.00 (+10.00%) As of 02:31 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Viracta Therapeutics Short Interest DataViracta Therapeutics (VIRX) has a short interest of 22,600 shares, representing 0.06% of the float (the number of shares available for trading by the public). This marks a -23.13% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.1, indicating that it would take 0.1 days of the average trading volume of 1.08 million shares to cover all short positions.Current Short Interest22,600 sharesPrevious Short Interest29,400 sharesChange Vs. Previous Month-23.13%Dollar Volume Sold Short$413.58Short Interest Ratio0.1 Days to CoverLast Record DateMay 31, 2025Outstanding Shares39,744,000 sharesShort Percent of Float0.06%Today's Trading Volume52,268 sharesAverage Trading Volume1,077,708 sharesToday's Volume Vs. Average5% Short Selling Viracta Therapeutics? Sign up to receive the latest short interest report for Viracta Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartVIRX Short Interest Over TimeVIRX Days to Cover Over TimeVIRX Percentage of Float Shorted Over Time Viracta Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/31/202522,600 shares $413.58 -23.1%0.1%0.1 $0.02 5/15/202529,400 shares $514.50 -26.3%N/A0.2 $0.02 4/30/202539,900 shares $833.91 +405.1%N/A0.3 $0.02 4/15/20257,900 shares $132.72 -21.0%N/A0 $0.02 3/14/202528,200 shares $733.20 +108.9%N/A0 $0.03 2/14/202523,200 shares $396.72 -87.4%N/A0 $0.02 1/31/2025184,200 shares $27.91 thousand -25.1%0.7%0.1 $0.15 1/15/2025246,000 shares $40.34 thousand -59.7%0.9%0.1 $0.16 12/31/2024609,900 shares $98.13 thousand -79.7%2.2%0.2 $0.16 12/15/20243,000,000 shares $608.10 thousand +89.9%10.7%1.4 $0.20 Get the Latest News and Ratings for VIRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Viracta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/30/20241,580,000 shares $221.20 thousand -24.8%5.7%0.8 $0.14 11/15/20242,100,000 shares $317.10 thousand -21.9%7.5%2 $0.15 10/31/20242,690,000 shares $542.84 thousand +144.6%9.7%1.9 $0.20 10/15/20241,100,000 shares $241.56 thousand -17.3%4.0%1.7 $0.22 9/30/20241,330,000 shares $307.76 thousand +1.5%4.8%2.1 $0.23 9/15/20241,310,000 shares $328.81 thousand +4.0%4.7%2.1 $0.25 8/31/20241,260,000 shares $269.14 thousand -50.4%4.6%2.1 $0.21 8/15/20242,540,000 shares $885.19 thousand +178.5%9.2%4.8 $0.35 7/31/2024912,000 shares $436.85 thousand -6.4%3.3%8.5 $0.48 7/15/2024974,800 shares $517.62 thousand +35.2%3.5%10.7 $0.53 6/30/2024721,000 shares $392.01 thousand +1.7%2.6%7 $0.54 6/15/2024708,900 shares $477.66 thousand +3.8%2.6%6.7 $0.67 5/31/2024682,700 shares $477.89 thousand +2.1%2.5%6.3 $0.70 5/15/2024668,400 shares $561.46 thousand -4.4%2.4%6.5 $0.84 4/30/2024699,400 shares $573.23 thousand +1.9%2.5%6.3 $0.82 4/15/2024686,700 shares $535.63 thousand +6.0%2.5%6.2 $0.78 3/31/2024648,000 shares $660.96 thousand +2.2%2.4%6.8 $1.02 3/15/2024634,300 shares $631.76 thousand -7.1%2.3%5.7 $1.00 2/29/2024683,000 shares $556.65 thousand +0.6%2.5%5 $0.82 2/15/2024678,800 shares $433.75 thousand +4.5%2.5%4.5 $0.64 1/31/2024649,900 shares $370.44 thousand +0.4%2.4%4 $0.57 1/15/2024647,500 shares $384.23 thousand -1.9%2.4%3.8 $0.59 12/31/2023660,300 shares $376.37 thousand -14.9%2.5%3.8 $0.57 12/15/2023776,100 shares $361.97 thousand +19.3%2.9%4.6 $0.47 11/30/2023650,700 shares $316.89 thousand -8.2%2.4%4.9 $0.49 11/15/2023708,700 shares $425.50 thousand +3.0%2.6%7.3 $0.60 10/31/2023688,200 shares $424.28 thousand +12.0%2.6%7.5 $0.62 10/15/2023614,700 shares $436.44 thousand -2.7%2.3%7.6 $0.71 9/30/2023632,000 shares $657.28 thousand -4.3%2.4%7 $1.04 9/15/2023660,200 shares $838.45 thousand -5.3%2.5%7.8 $1.27The 402 Dividend Achievers for 2025 (Ad)The 2025 Dividend Achievers List 📈 Discover more than 400 companies that have increased their dividends for 10 straight years. This FREE report reveals stocks that are committed to rewarding you and helping you passively boost your income.Don’t miss this valuable opportunity to build a stronger portfolio. 8/31/2023697,200 shares $1.00 million -4.4%2.6%6.8 $1.44 8/15/2023729,100 shares $947.83 thousand +5.2%2.7%4.5 $1.30 7/31/2023692,900 shares $1.07 million -3.9%2.6%2.8 $1.55 7/15/2023721,000 shares $1.05 million -1.0%2.7%2.9 $1.45 6/30/2023728,500 shares $1.03 million -7.8%2.8%3 $1.41 6/15/2023789,900 shares $1.26 million +14.0%3.0%3.3 $1.59 5/31/2023693,200 shares $921.96 thousand +12.4%2.6%3.2 $1.33 5/15/2023616,700 shares $807.88 thousand -2.2%2.3%3.4 $1.31 4/30/2023630,800 shares $813.73 thousand +2.0%2.4%8.4 $1.29 4/15/2023618,300 shares $902.72 thousand -2.5%2.3%9.6 $1.46 3/31/2023634,000 shares $1.01 million -19.5%2.4%8.4 $1.59 3/15/2023787,800 shares $1.33 million +51.7%3.0%8.7 $1.69 2/28/2023519,200 shares $882.64 thousand +3.9%2.0%4.9 $1.70 2/15/2023499,500 shares $994.01 thousand +5.6%1.9%4.5 $1.99 1/31/2023473,000 shares $983.84 thousand -2.5%1.8%3.8 $2.08 1/15/2023485,300 shares $1.10 million +3.2%1.8%3.9 $2.26 12/30/2022470,300 shares $686.64 thousand -15.1%1.8%3.8 $1.46 12/15/2022553,600 shares $1.06 million -0.1%2.1%5.2 $1.92 11/30/2022553,900 shares $1.29 million +7.3%2.1%5.1 $2.32 11/15/2022516,200 shares $1.50 million +8.8%2.0%4.8 $2.90 10/31/2022474,600 shares $1.87 million -9.6%1.9%4.7 $3.93 10/15/2022525,100 shares $1.97 million -4.4%2.0%5.1 $3.75 9/30/2022549,000 shares $2.34 million +9.3%2.1%5 $4.27 9/15/2022502,100 shares $2.81 million -3.9%2.0%2.6 $5.59 8/31/2022522,300 shares $2.12 million +0.6%2.0%2.3 $4.05 8/15/2022519,100 shares $2.29 million -8.2%2.0%2.2 $4.42 7/31/2022565,400 shares $1.88 million -16.1%1.9%2.2 $3.32 7/15/2022673,800 shares $2.99 million -32.5%2.3%2.5 $4.44 6/30/2022998,500 shares $3.87 million -48.5%3.4%3.2 $3.88 6/15/20221,940,000 shares $4.85 million -3.0%6.5%6.1 $2.50 5/31/20222,000,000 shares $4.24 million +8.7%6.7%8.1 $2.12 5/15/20221,840,000 shares $3.44 million -7.1%6.2%7.3 $1.87 4/30/20221,980,000 shares $5.05 million +16.5%6.7%6.2 $2.55 4/15/20221,700,000 shares $6.90 million +20.6%5.7%5.2 $4.06 3/31/20221,410,000 shares $6.71 million +20.5%4.8%4.7 $4.76 3/15/20221,170,000 shares $2.61 million +13.6%3.9%4.2 $2.23 2/28/20221,030,000 shares $2.81 million +7.8%3.5%3.5 $2.73 2/15/2022955,900 shares $2.98 million +26.0%3.2%3 $3.12 1/31/2022758,800 shares $2.03 million +5.5%2.7%2.9 $2.68 1/15/2022719,100 shares $2.28 million -15.4%2.5%3.3 $3.17 12/31/2021849,800 shares $3.10 million -2.7%3.0%3.7 $3.65 12/15/2021873,100 shares $3.12 million +30.4%3.1%4 $3.57 11/30/2021669,400 shares $3.09 million -24.3%2.4%3.8 $4.61 11/15/2021884,500 shares $4.93 million -15.0%3.1%5.5 $5.57 10/29/20211,040,000 shares $6.12 million -7.1%3.5%6.6 $5.88 10/15/20211,120,000 shares $7.25 million -1.8%3.8%7.5 $6.47 9/30/20211,140,000 shares $9.14 million -5.0%3.8%8.5 $8.02 9/15/20211,200,000 shares $10.08 million -9.1%4.0%5.5 $8.40 8/31/20211,320,000 shares $12.17 million -15.9%4.4%4.9 $9.22 8/13/20211,570,000 shares $16.11 million No Change5.3%5.7 $10.26The 402 Dividend Achievers for 2025 (Ad)The 2025 Dividend Achievers List 📈 Discover more than 400 companies that have increased their dividends for 10 straight years. This FREE report reveals stocks that are committed to rewarding you and helping you passively boost your income.Don’t miss this valuable opportunity to build a stronger portfolio. VIRX Short Interest - Frequently Asked Questions What is Viracta Therapeutics' current short interest? Short interest is the volume of Viracta Therapeutics shares that have been sold short but have not yet been closed out or covered. As of May 15th, traders have sold 29,400 shares of VIRX short. Learn More on Viracta Therapeutics' current short interest. Is Viracta Therapeutics' short interest increasing or decreasing? Viracta Therapeutics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 29,400 shares, a drop of 26.3% from the previous total of 39,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Viracta Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Viracta Therapeutics: Aspira Women's Health Inc. (1.19%), Galmed Pharmaceuticals Ltd. (8.48%), Protagenic Therapeutics, Inc. (25.79%), Entero Therapeutics, Inc. (4.38%), Aptevo Therapeutics Inc. (1.44%), Galera Therapeutics, Inc. (0.01%), Shuttle Pharmaceuticals Holdings, Inc. (11.51%), Vaccinex, Inc. (0.08%), Akanda Corp. (1.04%), Salarius Pharmaceuticals, Inc. (2.50%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($29.20 billion), Strategy Incorporated ($10.88 billion), iShares 20+ Year Treasury Bond ETF ($10.04 billion), Capital One Financial Co. ($5.51 billion), Charter Communications, Inc. ($5.00 billion), Super Micro Computer, Inc. ($4.43 billion), Apollo Global Management, Inc. ($4.02 billion), Hims & Hers Health, Inc. ($3.65 billion), VanEck Semiconductor ETF ($3.27 billion), and Coinbase Global, Inc. ($3.10 billion). View all of the most shorted stocks. What does it mean to sell short Viracta Therapeutics stock? Short selling VIRX is an investing strategy that aims to generate trading profit from Viracta Therapeutics as its price is falling. VIRX shares are trading down $0.00 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Viracta Therapeutics? A short squeeze for Viracta Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of VIRX, which in turn drives the price of the stock up even further. How often is Viracta Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VIRX, twice per month. The most recent reporting period available is May, 15 2025. More Short Interest Resources from MarketBeat Related Companies AWH Short Squeeze GLMD Short Squeeze PTIX Short Squeeze ENTO Short Squeeze APVO Short Squeeze GRTX Short Squeeze SHPH Short Squeeze VCNX Short Squeeze AKAN Short Squeeze SLRX Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:VIRX) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viracta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
